Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AST 001 - Ascentawits Pharmaceuticals

Next Previous
X
Search
Drug Profile

AST 001 - Ascentawits Pharmaceuticals

Alternative Names: AST-001 - Ascentawits Pharmaceuticals

Latest Information Update: 22 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascentawits Pharmaceuticals
  • Class Antineoplastics; Drug conjugates
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer; Solid tumours
  • Phase I Gastric cancer; Lung cancer

Most Recent Events

  • 07 Jul 2022 Phase-I/II clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06245330)
  • 07 Jul 2022 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in China (IV) (NCT06245330)
  • 31 Dec 2021 Phase-I clinical trials in Gastric cancer (IV), before December 2021 (Ascentawits Pharmaceuticals pipeline, February 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top